These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 18760379)

  • 1. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State-of-the-art genomics approaches in toxicology.
    Van Hummelen P; Sasaki J
    Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of toxicogenomics to drug development.
    Lakkis MM; DeCristofaro MF; Ahr HJ; Mansfield TA
    Expert Rev Mol Diagn; 2002 Jul; 2(4):337-45. PubMed ID: 12138498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S
    Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting drug-drug interactions in drug discovery: where are we now and where are we going?
    Hutzler M; Messing DM; Wienkers LC
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):51-8. PubMed ID: 15679172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When will the genomics investment pay off for antibacterial discovery?
    Mills SD
    Biochem Pharmacol; 2006 Mar; 71(7):1096-102. PubMed ID: 16387281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving drug safety using computational biology.
    Cook D
    IDrugs; 2010 Feb; 13(2):85-9. PubMed ID: 20127559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
    Burczynski ME
    Toxicol Lett; 2009 Apr; 186(1):18-21. PubMed ID: 19022363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing paradigm for prediction of development-limiting barriers and human drug toxicity.
    Sasseville VG; Lane JH; Kadambi VJ; Bouchard P; Lee FW; Balani SK; Miwa GT; Smith PF; Alden CL
    Chem Biol Interact; 2004 Nov; 150(1):9-25. PubMed ID: 15522258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive toxicogenomics in preclinical discovery.
    Barros SA; Martin RB
    Methods Mol Biol; 2008; 460():89-112. PubMed ID: 18449484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicogenomics in risk assessment: applications and needs.
    Boverhof DR; Zacharewski TR
    Toxicol Sci; 2006 Feb; 89(2):352-60. PubMed ID: 16221963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico methods for early toxicity assessment.
    Merlot C
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.